[go: up one dir, main page]

MX2019001093A - Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. - Google Patents

Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.

Info

Publication number
MX2019001093A
MX2019001093A MX2019001093A MX2019001093A MX2019001093A MX 2019001093 A MX2019001093 A MX 2019001093A MX 2019001093 A MX2019001093 A MX 2019001093A MX 2019001093 A MX2019001093 A MX 2019001093A MX 2019001093 A MX2019001093 A MX 2019001093A
Authority
MX
Mexico
Prior art keywords
methylphenidate
drugs
depth
processes
preparation
Prior art date
Application number
MX2019001093A
Other languages
English (en)
Other versions
MX375715B (es
Inventor
Chi Guochen
Guenther Sven
Bera Bindu
Mickle Travis
Bera Sanjib
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of MX2019001093A publication Critical patent/MX2019001093A/es
Publication of MX375715B publication Critical patent/MX375715B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente tecnología está dirigida a los profármacos y composiciones para el tratamiento de diversos trastornos y/o enfermedades, que comprenden metilfenidato, o derivados de metilfenidato, conjugados al menos a un alcohol, amina, oxoácido, tiol, o derivados de los mismos. En algunas modalidades, los conjugados incluyen además al menos un ligador. La presente tecnología también se refiere a la síntesis de metilfenidato, o derivados de metilfenidato, conjugado al menos a un alcohol, amina, oxoácido, tiol, o derivados de los mismos o combinaciones de los mismos.
MX2019001093A 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos. MX375715B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512658P 2011-07-28 2011-07-28
PCT/US2012/048641 WO2013016668A2 (en) 2011-07-28 2012-07-27 Methylphenidate-prodrugs, processes of making and using the same

Publications (2)

Publication Number Publication Date
MX2019001093A true MX2019001093A (es) 2019-07-04
MX375715B MX375715B (es) 2025-03-06

Family

ID=47601775

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016010664A MX362571B (es) 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
MX2019001093A MX375715B (es) 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos.
MX2013015088A MX341416B (es) 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016010664A MX362571B (es) 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013015088A MX341416B (es) 2011-07-28 2012-07-27 Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.

Country Status (29)

Country Link
US (4) US9079928B2 (es)
EP (2) EP3189840B1 (es)
JP (4) JP5976111B2 (es)
KR (5) KR20190085183A (es)
CN (2) CN103826633B (es)
AR (1) AR087390A1 (es)
AU (1) AU2012286683C1 (es)
BR (1) BR112014002084B1 (es)
CA (3) CA2984544C (es)
CL (1) CL2014000210A1 (es)
CO (1) CO6900135A2 (es)
DK (1) DK2736510T3 (es)
ES (2) ES2883259T3 (es)
HR (1) HRP20170555T1 (es)
HU (1) HUE032113T2 (es)
IL (5) IL230650A (es)
LT (1) LT2736510T (es)
MX (3) MX362571B (es)
MY (1) MY162499A (es)
PH (1) PH12014500049A1 (es)
PL (1) PL2736510T3 (es)
PT (1) PT2736510T (es)
RS (1) RS55812B1 (es)
RU (1) RU2573835C2 (es)
SG (1) SG10201606225XA (es)
SI (1) SI2736510T1 (es)
UA (1) UA112654C2 (es)
WO (1) WO2013016668A2 (es)
ZA (1) ZA201308766B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112654C2 (uk) * 2011-07-28 2016-10-10 Кемфарм Інк. Проліки метилфенідату
NZ722096A (en) * 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
WO2014054058A2 (en) * 2012-10-05 2014-04-10 Sphaera Pharma Pvt. Ltd. Novel compounds, their synthesis and their uses
WO2015001499A2 (en) * 2013-07-04 2015-01-08 Mahesh Kandula Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping
CN104418797B (zh) * 2013-08-26 2019-04-19 上海医药集团股份有限公司 哌甲酯、右哌甲酯的制备方法、其中间体及制备方法
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2017048720A1 (en) * 2015-09-15 2017-03-23 Praxis Biosciences, Llc Prodrugs of fencamfamine
IL266223B2 (en) 2016-10-31 2024-04-01 Biocryst Pharm Inc Prodrugs of kallikrein inhibitors
WO2018107131A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
SMT202400217T1 (it) 2016-12-11 2024-07-09 Zevra Therapeutics Inc Composizioni comprendenti profarmaci di metilfenidato, processi per la loro produzione e uso
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
US20200114014A1 (en) * 2017-04-11 2020-04-16 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Amide and Imide Prodrugs of Amphetamine Compounds and Uses Thereof
WO2019216664A1 (ko) 2018-05-10 2019-11-14 주식회사 헬릭스미스 주의력결핍과잉행동장애 치료용 생약조성물
WO2020067507A1 (ja) * 2018-09-28 2020-04-02 生化学工業株式会社 第１級アミン化合物又は第２級アミン化合物－酸性多糖コンジュゲートとその製造方法
US11136295B2 (en) * 2018-10-29 2021-10-05 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same
CN118324811A (zh) * 2019-06-28 2024-07-12 福建盛迪医药有限公司 神经激肽-1拮抗剂
EP4072561A4 (en) 2019-12-11 2023-11-29 Inspirna, Inc. CANCER TREATMENT METHODS
IL295986A (en) * 2020-02-29 2022-10-01 Kempharm Inc Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP4267118A4 (en) * 2020-12-24 2025-01-22 Axelyf ehf. XANTHOPHYLL DERIVATIVES
AU2023276599A1 (en) 2022-05-25 2024-12-05 Imagenebio, Inc. Mek inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428935A (en) * 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
WO1999036403A1 (en) * 1998-01-13 1999-07-22 The Trustees Of The University Of Pennsylvania Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
MXPA02007252A (es) * 2000-01-28 2003-01-29 Rohm & Haas Compuestos farmaceuticos con propiedades mejoradas.
US20020132793A1 (en) 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
CA2420569A1 (en) * 2000-08-28 2002-03-07 Mel H. Epstein Use of threo-methylphenidate compounds to enhance memory
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
WO2004080959A2 (en) * 2003-03-07 2004-09-23 Isp Investments Inc. Process for the preparation of dexmethylphenidate hydrochloride
FI120187B (fi) * 2003-03-14 2009-07-31 Outotec Oyj Menetelmä prosessin säätämiseksi
WO2006047330A2 (en) 2004-10-22 2006-05-04 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2007022535A2 (en) 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
EP2121029A2 (en) * 2006-12-05 2009-11-25 Neurogesx, Inc. Prodrugs and methods of making and using the same
WO2008073918A1 (en) 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
WO2008097546A2 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
CN101631770A (zh) * 2007-02-02 2010-01-20 科露西德医药品公司 抑制胆碱酯酶的化合物
EP2109465B1 (en) 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
BRPI0808962A2 (pt) * 2007-03-15 2014-08-26 Sun Pharma Advanced Res Co Ltd Agente para drogas
EP2152690B1 (en) * 2007-05-23 2012-01-11 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
UA112654C2 (uk) * 2011-07-28 2016-10-10 Кемфарм Інк. Проліки метилфенідату
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds

Also Published As

Publication number Publication date
PH12014500049A1 (en) 2016-07-29
EP3189840A1 (en) 2017-07-12
IL269322A (en) 2019-11-28
MX341416B (es) 2016-08-19
IL230650A0 (en) 2014-03-31
KR101616111B1 (ko) 2016-04-27
IL262493B (en) 2019-10-31
HUE032113T2 (en) 2017-09-28
UA112654C2 (uk) 2016-10-10
AU2012286683C1 (en) 2016-04-21
SG10201606225XA (en) 2016-09-29
US20140243291A1 (en) 2014-08-28
CA3123900A1 (en) 2013-01-31
IL269322B (en) 2020-05-31
KR20140081761A (ko) 2014-07-01
MX2013015088A (es) 2014-02-11
EP3189840B1 (en) 2021-05-19
US20190142815A1 (en) 2019-05-16
JP5976111B2 (ja) 2016-08-23
KR20190085183A (ko) 2019-07-17
BR112014002084B1 (pt) 2022-03-29
JP2014521656A (ja) 2014-08-28
WO2013016668A3 (en) 2013-03-21
EP2736510B1 (en) 2017-03-01
IL230650A (en) 2016-12-29
US10231960B2 (en) 2019-03-19
DK2736510T3 (en) 2017-04-24
WO2013016668A2 (en) 2013-01-31
RS55812B1 (sr) 2017-08-31
LT2736510T (lt) 2017-04-25
US20150266911A1 (en) 2015-09-24
AR087390A1 (es) 2014-03-19
US20170049765A1 (en) 2017-02-23
CA2837732C (en) 2018-03-20
MY162499A (en) 2017-06-15
SI2736510T1 (sl) 2017-05-31
CN107261148A (zh) 2017-10-20
RU2573835C2 (ru) 2016-01-27
IL254143A0 (en) 2017-10-31
MX362571B (es) 2019-01-25
JP2016222692A (ja) 2016-12-28
CL2014000210A1 (es) 2014-09-26
HRP20170555T1 (hr) 2017-06-16
US9453037B2 (en) 2016-09-27
EP2736510A4 (en) 2015-02-25
ES2883259T3 (es) 2021-12-07
JP6505822B2 (ja) 2019-04-24
KR20160047599A (ko) 2016-05-02
JP2019112462A (ja) 2019-07-11
IL254143B (en) 2018-11-29
PL2736510T3 (pl) 2017-07-31
CA2984544A1 (en) 2013-01-31
KR20190085184A (ko) 2019-07-17
CO6900135A2 (es) 2014-03-20
CA2984544C (en) 2021-08-31
AU2012286683B2 (en) 2015-12-17
EP2736510A2 (en) 2014-06-04
IL262493A (en) 2018-12-31
IL246503A (en) 2017-09-28
KR101869885B1 (ko) 2018-06-25
MX375715B (es) 2025-03-06
CA2837732A1 (en) 2013-01-31
CN107261148B (zh) 2021-07-13
JP6731090B2 (ja) 2020-07-29
RU2014107678A (ru) 2015-09-10
JP6272403B2 (ja) 2018-01-31
BR112014002084A2 (pt) 2017-06-13
KR20180069934A (ko) 2018-06-25
US9079928B2 (en) 2015-07-14
JP2018076359A (ja) 2018-05-17
ES2621306T3 (es) 2017-07-03
CN103826633B (zh) 2017-05-24
NZ618113A (en) 2015-06-26
CN103826633A (zh) 2014-05-28
PT2736510T (pt) 2017-04-05
ZA201308766B (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MX2019001093A (es) Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
MX2019003738A (es) Compuestos antivirales.
BRPI0910388A2 (pt) agentes terapêutico antivirais.
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112012020791A2 (pt) produção de 6'-o-sialillactose e intermediários
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
HN2010002582A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
GT201300025A (es) Derivados anticancerosos, su preparación y su aplicación en terapeútica
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR11627A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
CR11106A (es) Inhibidores de cinasa p710 s6
UY31922A (es) Compuestos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
HN2012000217A (es) Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos.
BR112013023266B8 (pt) inibidores da girase tricíclicos
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
BRPI1014802B8 (pt) profármacos de triptolida.
BRPI1008855B8 (pt) derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona

Legal Events

Date Code Title Description
FG Grant or registration